Sanford Burnham Prebys researchers reported that upregulating SORLA suppresses multiple pathological features in an aged mouse model of tauopathy. In Science Advances, the team tied the trafficking receptor SORLA to reductions in tau-driven damage, suggesting a potential therapeutic target beyond amyloid-focused pathways. The study built on prior evidence linking SORLA to amyloid-beta regulation, while focusing on whether and how the receptor affects tau tangles in vivo. The authors reported protective effects spanning several aspects of tauopathy pathogenesis, positioning SORLA as a candidate to enhance neuroprotection when tau aggregates drive synaptic and cognitive decline. Investigators noted that SORLA is expressed in both neurons and glia in mouse and human brain, supporting translational relevance for follow-on target validation and mechanism work.